In today's fireside chat , Michael Betel, President and Founder of the Fatty Liver Alliance, and Professor @GiadaSebastiani, Hepatologist at @mcgillu, explore the comprehensive management of fatty liver disease, now termed MASLD, and reflect on her recently published perspective paper, "Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease". Giada Sebastiani emphasized the necessity of a holistic, multidisciplinary approach to treating MASLD, acknowledging the complexity of the disease that affects multiple systems beyond the liver. She highlighted the recent approval of Rezdiffra for treating MASH in the U.S., which should be complemented with lifestyle changes such as diet and exercise. Dr. Sebastiani underscored that while pharmacological solutions are crucial, they must be integrated with behavioral interventions and lifestyle modifications to be truly effective. Here are the three key takeaways from the discussion: 1. Holistic and Multidisciplinary Approach: Effective management of MASLD requires a comprehensive approach that integrates pharmacological treatments with lifestyle modifications such as diet, exercise, and behavioral interventions. Addressing the disease's multifaceted nature, which affects multiple systems beyond the liver, is essential for improving patient outcomes. 2. Early Intervention and Personalized Care: Early intervention targeting upstream issues like obesity, type 2 diabetes, and eating disorders is crucial in preventing the progression of MASLD. Personalized care tailored to individual patient characteristics enhances the effectiveness of treatment and promotes better health outcomes. 3. Patient Education and Advocacy: Empowering patients with knowledge about MASLD and available treatment options is vital for enabling informed decision-making and encouraging early diagnosis and intervention. Increased awareness and advocacy efforts are essential for improving the management of MASLD and supporting affected individuals. Link to blog with video: fattyliver.ca/blog/f/masld-p… @livertwitter @liverX

Dr. Mark Swain, Hepatologist answers an audience question at our Calgary event and shares one real world patient story about Ozempic and the impact it had on their life and daily routine. #livertwitter #liverX @novonordisk @AASLDtweets @EASLnews @CASLupdates @CanNASHNetwork fattyliver.ca/blog/f/ozempic…

Millions are affected by fatty liver disease, and raising awareness is crucial. Wendy Schaufert has dedicated 10 years to working with patients, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly NAFLD/NASH. Key takeaways: from this excellent video: youtu.be/pyDY53eecQQ 1. Risk Factors: Obesity, diabetes, and insulin resistance significantly increase the risk of developing MASLD and MASH. 2. Diagnosis: Often silent, the disease is usually detected through routine blood work, ultrasounds, and non-invasive liver stiffness tests like SWI and FibroScan. 3. Management: Lifestyle changes, including weight loss, exercise, and healthy eating, are vital. Even a 5-10% weight loss can make a significant difference. 4. Heart Health: Those with fatty liver disease are at a higher risk of heart-related issues. 5. Awareness and Advocacy: Early detection and management can prevent progression to severe liver conditions like cirrhosis. Education and support are essential. Wendy's work and resources like we offer on our Fatty Liver Alliance website, offer valuable information to help manage and understand this condition better. Let's continue to advocate for awareness and healthier lifestyles! #GlobalFattyLiverDay #FattyLiverDisease #MASLD #MASH #HealthAwareness #LiverHealth #PatientAdvocacy @AASLDtweets @easl @CASLupdates @CanNASHNetwork @LiverNurseCA @FamPhysicians @CIHR_IRSC @GlobalLiver @ISGLOBALorg Link to video: youtu.be/pyDY53eecQQ